Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab

Cited by (999)

Items 901–999 of 999

1. Neurological Adverse Effects of Immune Checkpoint Inhibitors and Chimeric Antigen Receptor T-Cell Therapy
   Farhan Khalid, Rajshree Gupta, Rajvi Gor, Dairya Gor, Vinit Singh, Hussam S. Eltoukhy · 2023 · World Journal of Oncology
2. Immune checkpoint inhibitors in advanced cutaneous melanoma: a systematic review and meta-analysis of efficacy and review of characteristics
   Sara Mahdiabadi, Sara Momtazmanesh, Amirali Karimi, Nima Rezaei · 2023 · Expert Review of Anticancer Therapy
3. Ipilimumab in non-small cell lung cancer and small-cell lung cancer: new knowledge on a new therapeutic strategy
   Erika Rijavec, Carlo Genova, Giulia Barletta, Giovanni Burrafato, Federica Biello, Maria Giovanna Dal Bello, Simona Coco, Anna Truini, Angela Alama, Francesco Boccardo et al. · 2014 · Expert Opinion on Biological Therapy
4. Checkpoint Inhibitors, Palliative Care, or Hospice
   Mellar P. Davis, Rajiv Prasanna Panikkar · 2018 · Current Oncology Reports
5. Autoimmune Bell’s Palsy Following Immunotherapy For Metastatic Melanoma: A Report of 2 Cases
   Daniel P. Zieman, Arthur Edward Frankel · 2019 · Journal of Immunotherapy
6. Acute and Long-term Adverse Events Associated With Checkpoint Blockade
   Marianne J Davies · 2019 · Seminars in Oncology Nursing
7. Immune-related adverse events as predictors of response in cancer patients undergoing immunotherapy
   A. Ezponda Casajús, Marta Calvo Imirizaldu, J.P. de Torres Tajes, Alejandra García-Baizán, Eduardo Castañón Álvarez, David Cano Rafart, Isabel Vivas Pérez, G. Bastarrika Alemañ · 2020 · Radiología (English Edition)
8. CMV coinfection in treatment refractory immune checkpoint inhibitor colitis
   Kevin B. Harris, Pauline Funchain, Brian B. Baggott · 2020 · BMJ Case Reports
9. Hypophysitis related to immune checkpoint inhibitors: An intriguing adverse event with many faces
   Maria V. Deligiorgi, Charis A. Liapi, Dimitrios T. Trafalis · 2021 · Expert Opinion on Biological Therapy
10. Drug-induced liver injury: An overview and update
    Yujie Wang, Wen Xie · 2023 · Gastroenterology & Endoscopy
11. Standardizing Central Venous Catheter Care by Using Observations From Patients With Cancer
    Saul N. Weingart, Candace Hsieh, Sharon Lane, Angela M. Cleary · 2014 · Clinical journal of oncology nursing
12. Radiological manifestations of immune‐related adverse effects observed in patients with melanoma undergoing immunotherapy
    Parveen Sidhu, Alexander Maxwell Menzies, Georgina Venetia Long, Matteo Salvatore Carlino, Shirleen Lorens, Rony Kapoor · 2017 · Journal of Medical Imaging and Radiation Oncology
13. Cytomegalovirus infection among patients with cancer receiving immune checkpoint inhibitors
    Kavea Panneerselvam · 2022 · Annals of Gastroenterology
14. Current landscape and tailored management of immune-related adverse events
    Wenhui Liu, Zhiying Luo, Yiping Liu, Bao Sun · 2023 · Frontiers in Pharmacology
15. Potential application mechanism of traditional Chinese medicine in treating immune checkpoint inhibitor-induced colitis
    Jing Wang, Ziyue Guo, Mengyi Shen, Qi Xie, Hongjie Xiang · 2024 · Frontiers in Immunology
16. Two Cases of Nivolumab Re-Administration after Pneumonitis as Immune-Related Adverse Events
    Keisuke Imafuku, Koji Yoshino, Kei Yamaguchi, Satoshi Tsuboi, Kuniaki Ohara, Hiroo Hata · 2017 · Case Reports in Oncology
17. Discovery of 4H-chromeno[2,3-d]pyrimidin-4-one derivatives as senescence inducers and their senescence-associated antiproliferative activities on cancer cells using advanced phenotypic assay
    Sangmi Oh, Ji Young Lee, Inhee Choi, Arnaud Ogier, Do Yoon Kwon, Hangyeol Jeong, Sook Jin Son, Youngmi Kim, Haejin Kwon, Seijin Park et al. · 2020 · European Journal of Medicinal Chemistry
18. Challenges of Cancer Immunotherapy during the COVID-19 Pandemic
    Nicole M. Kuderer, Gary H. Lyman · 2020 · Cancer Investigation
19. Severe thyrotoxicosis induced by tislelizumab: a case report and literature review
    Liman Huo, Chao Wang, Haixia Ding, Xuelian Shi, Bin Shan, Ruoying Zhou, Ping Liang, Juan Hou · 2023 · Frontiers in Oncology
20. Talimogene laherparepvec in the treatment of melanoma
    Elizabeth S. Appleton, Samantha Jane Turnbull, Christy Ralph, Emma J. West, Karen J. Scott, Kevin Joseph Harrington, Hardev Pandha, Alan A. Melcher · 2015 · Expert Opinion on Biological Therapy
21. A Rare Case of Immune-Mediated Primary Adrenal Insufficiency With Cytotoxic T-Lymphocyte Antigen-4 Inhibitor Ipilimumab in Metastatic Melanoma of Lung and Neck of Unknown Primary
    Salem Gaballa, Kyaw M Hlaing, Nathan Mahler, Safa Moursy, Ameenjamal Ahmed · 2020 · Cureus
22. Role of gut microbiome in the outcome of cancer immunotherapy
    Junting Ma, Wenwen Zhu, Beixing Liu · 2021 · International Journal of Cancer
23. Mechanistic basis for Cancer Immune Evasion and role of immune checkpoint blockades in Immuno-Oncology
    Benjamin Ayodipupo Babalola, Gboyega Ebenezer Adebami, Oluwamayowa Akinsuyi · 2021 · Global Journal of Cancer Therapy
24. Squamous cell carcinoma of the lung: improving the detection and management of immune-related adverse events
    Lara Ann Kujtan, Rama Krishna Kancha, Beth Gustafson, Lindsey Douglass, Christopher RH Ward, Blake Buzard, Janakiraman Subramanian · 2022 · Expert Review of Anticancer Therapy
25. Ipilimumab in the treatment of advanced melanoma – a clinical update
    Dae Won Kim, Van Anh Trinh, Wen‐Jen Hwu · 2014 · Expert Opinion on Biological Therapy
26. Safe Transition to Pembrolizumab following Ipilimumab-Induced Guillain-Barré Syndrome: A Case Report and Review of the Literature
    Nicholas Gravbrot, Katalin H. Scherer, Srinath Sundararajan · 2019 · Case Reports in Oncological Medicine
27. Role of Abdominal and Pelvic CT Scans in Diagnosis of Patients with Immunotherapy-Induced Colitis
    Juan J. Ibarra-Rovira, Selvi Thirumurthi, Melissa W. Taggart, Bulent Yilmaz, Heather Yan Lin, Linda Zhong, Chinenye Lynette Ejezie, Fechukwu Akhmedzhanov, Abdulrazzak Zarifa, Cheuk Hong Leung et al. · 2022 · Journal of Immunotherapy and Precision Oncology
28. Opportunistic Infections and Immune-Related Adverse Events Associated with Administering Immune Checkpoint Inhibitors: A Narrative Review
    Ranferi Ocaña‐Guzmán, Diego Osorio-Pérez, Leslie Chávez‐Galán · 2023 · Pharmaceuticals
29. Relationship of Immune-Related Adverse Events with Tumor Response and Prognosis in Esophageal Squamous Cell Carcinoma Following Nivolumab Monotherapy
    Yoichi Hamai, Yuta Ibuki, Tomoaki Kurokawa, Ryosuke Hirohata, Manato Ohsawa, Nao Kitasaki, Manabu Emi, Morihito Okada · 2024 · Cancers
30. Differential safety profiles of durvalumab monotherapy and durvalumab in combination with tremelimumab in adult patients with advanced cancers
    Claire Morgan, John F. Kurland, Mayur Patel, Cathy O’Brien, Pamela Concepcion, Gary Joseph Doherty, Stephan Hois, Alejandra Negro, Dejan Pavlović, Karen A Robbins · 2025 · Journal for ImmunoTherapy of Cancer
31. Targeting Immune Checkpoints in Melanoma: An Update
    Rodrigo Ramella Munhoz, Alejandro Falcón, Vanessa A. Reed, Michael Andrew Postow · 2015 · Melanoma Management
32. Advances in immunotherapy for non-small cell lung cancer.
    Karen L. Reckamp · 2015 · PubMed
33. Immune-mediated adverse events in immune checkpoint inhibitors therapy: literature review
    Marina A. Lyadova, Vladimir Konstantinovich Lyadov · 2021 · Journal of Modern Oncology
34. Novel Cellular and Immunotherapy: Toxicities and Perioperative Implications
    ALESSANDRO DE CAMILLI, Gregory W. Fischer · 2023 · Current Oncology
35. Primer on Immuno-Oncology and Immune Response
    Rajni Kannan, Kathleen M. Madden, Stephanie Andrews · 2014 · Clinical journal of oncology nursing
36. Colitis Associated with Biological Agents
    Khaldoon Khirfan, Martin G. Kistin · 2014 · Digestive Diseases and Sciences
37. Anticytotoxic T-Lymphocyte Antigen-4 Induced Autoimmune Hypophysitis: A Case Report and Literature Review
    Deborah Majchel, Mary T. Korytkowski · 2015 · Case Reports in Endocrinology
38. Side Effects of Targeted Therapies: Rash
    Beth Eaby‐Sandy, Kathy Lynch · 2014 · Seminars in Oncology Nursing
39. Ipilimumab may increase the severity of cutenaous toxicity related to radiotherapy
    Melek Karakurt Eryılmaz, Hasan Mutlu, Derya Kıvrak Salim, Fatma Yalçın Müsri, Deniz Güncel Tural, İbrahim Başsorgun, Hasan Şenol Çoşkun · 2015 · Journal of Oncology Pharmacy Practice
40. Pancreatitis associated with newer classes of antineoplastic therapies
    Gerald H. Clamon, Ravi Patel, Sarah L. Mott · 2017 · The Journal of Community and Supportive Oncology
41. Checkpoint Inhibitors in Breast Cancer - Current Status and Future Directions
    Joachim Bischoff · 2018 · Breast Care
42. Effets secondaires digestifs et hépatiques des inhibiteurs du checkpoint immunitaire (Immune checkpoint inhibitors : anti-CTLA-4 et anti-PD-1/PD-L1) : aspects anatomocliniques
    Barbara Papouin, Charlotte Mussini, Eléonora De Martin, Catherine Guettier · 2018 · Annales de Pathologie
43. Vaccine protection against rectal acquisition of SIVmac239 in rhesus macaques
    Lucas Gonzalez-Nieto, Isabelle M. Castro, Georg F. Bischof, Young Chul Shin, Michael J. Ricciardi, Varian K. Bailey, Christine M. Dang, Núria Pedreño-López, Diogo M. Magnani, Keisuke Ejima et al. · 2019 · PLoS Pathogens
44. Transient acantholytic dermatosis in a patient with prostate cancer
    MS Khan, Maham Khan, Ohara Aivaz · 2020 · Dermatology Online Journal
45. Hepatobiliary Adverse Events
    Hamzah Abu‐Sbeih, Yinghong Wang · 2020 · Advances in experimental medicine and biology
46. Advances in immune neoadjuvant/adjuvant therapy‐related adverse events of non‐small cell lung cancer
    Qingchun Zhao, Chao Liu, Hongyu Liu, Jun Chen · 2020 · Asia-Pacific Journal of Clinical Oncology
47. Association of Celiac Disease With Pembrolizumab
    Ashish Sethi, Alexander M. Helfand, Lamé Balikani, Mark L. Bunker, Gene Grant Finley · 2021 · Cureus
48. Gastrointestinal toxicity of systemic oncology immunotherapy
    Jan Bureš, Darina Kohoutová, Miroslav Zavoral · 2022 · Klinicka onkologie
49. Immune therapy for hepatocellular carcinoma
    Yaron Ilan · 2013 · Hepatology International
50. Enhanced Anti-tumor Reactivity of Cytotoxic T Lymphocytes Expressing PD-1 Decoy
    Jae Hun Shin, Hyung Bae Park, Kyungho Choi · 2016 · Immune Network
51. Manipulating the Immune System With Checkpoint Inhibitors for Patients With Metastatic Sarcoma
    Sandra P. D’Angelo · 2016 · American Society of Clinical Oncology Educational Book
52. A case of pembrolizumab-induced autoimmune haemolytic anaemia with polymyalgia rheumatica
    Bertrand Robilliard, Erik Arnaud, Lauris Gastaud, Jonathan Broner · 2018 · European Journal of Cancer
53. Combination checkpoint inhibitor therapy induces multiple immune major related adverse events in the treatment of vaginal melanoma: A cautionary case report
    T. Graham Norwood, Michelle Joy Wang, Warner King Huh · 2019 · Gynecologic Oncology Reports
54. Modernizing adverse events analysis in oncology clinical trials using alternative approaches: rationale and design of the MOTIVATE trial
    Bastien Cabarrou, Carlos Gomez‐Roca, Marie Viala, Audrey Rabeau, Rodolphe Paulon, Delphine Loirat, Nadia Munsch, Jean‐Pierre Delord, Thomas Filleron · 2020 · Investigational New Drugs
55. Fulminant Hepatic Failure after Chemosaturation with Percutaneous Hepatic Perfusion and Nivolumab in a Patient with Metastatic Uveal Melanoma
    Lindsey N. Teal, Jeffrey Thomas Yorio · 2021 · Case Reports in Oncological Medicine
56. Understanding and Managing Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Patients With Advanced Melanoma
    Alyona Weinstein, RuthAnn Gordon, Mary Kate Kasler, Matthew M. Burke, Smita Ranjan, Jackie Hodgetts, Vanessa A. Reed, Yelena Shames, Nana A. Prempeh-Keteku, Karla Lingard · 2017 · Journal of the Advanced Practitioner in Oncology
57. Tumor neoantigens derived from RNA editing events show significant clinical relevance in melanoma patients treated with immunotherapy
    Qicheng Lu, Wenhao Zhou, Ligang Fan, Tian Ding, Wei Wang, Xiaodong Zhang · 2023 · Anti-Cancer Drugs
58. CD276 Promotes an Inhibitory Tumor Microenvironment in Hepatocellular Carcinoma and is Associated with Poor Prognosis
    Wenfeng Liu, Qiu-Yu Jiang, Zhuoran Qi, Feng Zhang, Wenqing Tang, Haoqi Wang, Ling Dong · 2024 · Journal of Hepatocellular Carcinoma
59. Mechanistic and therapeutic advances in immune-mediated gastrointestinal disorders
    Nahir Garabatos, Edgar Angelats, Pere Santamaría · 2025 · Journal of Allergy and Clinical Immunology
60. Regulatory T Cell Depletion in Cancer: Challenges, Opportunities, and Future Directions for Antibody Development
    Mariela Navarrete, Cristóbal Costoya, Felipe Gálvez‐Cancino, Karl S. Peggs, Aurélien Marabelle, Sergio A. Quezada · 2025 · Annual Review of Medicine
61. Adverse Events of Novel Therapies for Hematologic Malignancies: What Emergency Physicians Should Know
    Mohsin Shah, Eva Rajha, Courtney Denton Dinardo, Erin Muckey, William G. Wierda, Sai‐Ching J. Yeung · 2019 · Annals of Emergency Medicine
62. Case Report: Severe cutaneous adverse event associated with checkpoint inhibition in the setting of CAR T-cell therapy: beyond CRS
    Chiara Masucci, Sara Pepe, Ursula La Rocca, Veronica Zullino, Maria Stefania De Propris, Walter Barberi, Anna Paola Iori, Sabina Martelli, Franco Ruberto, Maurizio Martelli et al. · 2023 · Frontiers in Oncology
63. Ipilimumab-Induced Autoimmune Hypophysitis: Diagnostic and Management Challenges Illustrated by a Clinical Case
    Pedro Marques, Ashley Barry Grossman · 2015 · Acta Médica Portuguesa
64. Systemic Therapy for Bladder Cancer Finally Comes into a New Age
    Matthew R. Zibelman, Elizabeth R. Plimack · 2016 · Future Oncology
65. Outcomes in Melanoma Patients Treated with BRAF/MEK-Directed Therapy or Immune Checkpoint Inhibition Stratified by Clinical Trial versus Standard of Care
    Chloe Goldman, Jeremy Tchack, Eric Michael Robinson, Sung Won Han, Una Moran, David Polsky, Russell S. Berman, Richard L. Shapiro, Patrick Alexander Ott, Iman Osman et al. · 2017 · Oncology
66. Emerging role of nivolumab in the management of patients with non-small-cell lung cancer: current data and future perspectives
    Emily Feld, Leora Horn · 2017 · OncoTargets and Therapy
67. How should we diagnose and manage checkpoint inhibitor-associated colitis?
    Freeha Khan, Pauline Funchain, Ana E. Bennett, Tracy Lynn Hull, Bo Shen · 2018 · Cleveland Clinic Journal of Medicine
68. Immune-Mediated Colitis
    Tara Menon, Anita Afzali · 2019 · Current Treatment Options in Gastroenterology
69. Early 3+3 Trial Dose-Escalation Phase I Clinical Trial Design and Suitability for Immune Checkpoint Inhibitors
    Osama E. Rahma, Joshua E. Reuss, Anita Giobbie‐Hurder, Ghazaleh Shoja E Razavi, Osama Abu-Shawer, Pooja Mehra, Seema Gupta, Richard M Simon, Samir N. Khleif · 2020 · Clinical Cancer Research
70. Colonoscopic evaluation of diarrhea/colitis occurring as an immune-related adverse event
    Yohei Yamauchi, Makoto Arai, Naoki Akizue, Yuki Ohta, Kenichiro Okimoto, Tomoaki Matsumura, Meng Fan, Chiaki Imai, Akinobu Tawada, Jun Kato et al. · 2020 · Japanese Journal of Clinical Oncology
71. Dermatologic infections in cancer patients treated with checkpoint inhibitors
    Mytrang H. Do, Dulce M. Barrios M.S, Gregory S. Phillips, Michael Andrew Postow, Allison Betof Warner, Jonathan E. Rosenberg, Sarah J. Noor, Alina Markova, Mario E. Lacouture · 2021 · Journal of the American Academy of Dermatology
72. Reduction of Nodular Growth Pattern of Metastatic Uveal Melanoma after Radioembolization of Hepatic Metastases
    Kevin M. Halenda, Ragini Reiney Kudchadkar, David H. Lawson, Darren D. Kies, Kristen E. Zhelnin, Alyssa M. Krasinskas, Hans E. Grossniklaus · 2015 · Ocular Oncology and Pathology
73. A case of Stevens–Johnson syndrome in a patient on ipilimumab
    Mohini Pathria, Jyoti Pathria Mundi, Joshua W. Trufant · 2016 · International Journal of Case Reports and Images
74. Ipilimumab-related hypophysitis may precede severe CNS immune attack
    Thibaud Koessler, Timothée Olivier, Sarah Fertani, Eliana Marinari, Valérie Dutoit, P.-Y. Dietrich · 2016 · Annals of Oncology
75. Analysis of B7-H4 expression in metastatic pleural adenocarcinoma and therapeutic potential of its antagonists
    Cheng Chen, Qiu‐Xia Qu, Fang Xie, Weidong Zhu, Yehan Zhu, Jianan Huang · 2017 · BMC Cancer
76. Rare side effect of adjuvant ipilimumab after surgical resection of melanoma: Guillain-Barré syndrome
    Rohini J. Patel, Michael A. Liu, Akshay Amaraneni, Simran K. Sindhu · 2017 · BMJ Case Reports
77. Pitfalls and Immune-Related Adverse Events
    Amir Iravani, Rodney J. Hicks · 2019 · Springer eBooks
78. Abdominal CT manifestations of adverse events to immunotherapy: a primer for radiologists
    Ali Pourvaziri, Anushri Parakh, Pierpaolo Biondetti, Dushyant V. Sahani, Avinash R. Kambadakone · 2020 · Abdominal Radiology
79. Acute pneumothorax due to immunotherapy administration in non-small cell lung cancer
    Chrysanthi Sardeli, Paul Zarogoulidis, Κonstantinos Romanidis, Panagoula Oikonomou, Konstantinos G. Sapalidis, Haidong Huang, Chong Bai, Wolfgang Hohenforst‐Schmidt, Kosmas Tsakiridis, Bojan Zarić et al. · 2020 · Respiratory Medicine Case Reports
80. A Multicentric, Retrospective, Real-world Study on Immune-related Adverse Events in Patients with Advanced Non-small Cell Lung Cancers Treated with Pembrolizumab Monotherapy
    A. Lerner, Alvin J. X. Lee, Huan Yan, Jennifer van Griethuysen, A.D. Bartlett, Mesel Veli, Yanrong Jiang, Marilan Luong, Nabeel Naban, Claire Kane et al. · 2024 · Clinical Oncology
81. Endocrine adverse events in patients with cancer receiving perioperative immune checkpoint blockade: a meta-analysis of randomized controlled trials
    Susu Zhou, Nobuyuki Horita, Theresa H. Shao, Matthew D. Harrington, Yu Fujiwara · 2024 · Therapeutic Advances in Medical Oncology
82. Gastrointestinal toxicities associated with immune checkpoint inhibitors therapy: risks and management
    Carolina Colli Cruz, Maria Julia Moura Nascimento Santos, Sharada Wali, Krishnavathana Varatharajalu, Anusha Shirwaikar Thomas, Yinghong Wang · 2025 · Immunotherapy
83. Ipilimumab Pharmacotherapy in Patients with Metastatic Melanoma
    Joanne Jeter, Lee D. Cranmer, Evan M. Hersh · 2012 · Clinical Medicine Insights Oncology
84. Pembrolizumab in the Management of Metastatic Melanoma
    Lavinia Anne Spain, Eugenie Younger, Emine Hatipoglu, James Larkin · 2015 · Melanoma Management
85. Pathologie der Nebenwirkungen von Immune-Checkpoint-Inhibitoren
    Viktor Hendrik Koelzer, Kathrin Glatz, Lukas Bubendorf, A. Weber, Ariana Gaspert, Gieri Cathomas, Alessandro Lugli, Alfred Zippelius, Werner Kempf, Kirsten D. Mertz · 2017 · Der Pathologe
86. Evaluating the effect of PD-1 inhibitors on left ventricular function in lung cancer with noninvasive myocardial work
    Xia Li, Chujun Wang, Ruirui Kang, Yu Zhao, Lili Chen, Fengzhen Liu, Xiaolin Wang, Yulan Peng, Chunquan Zhang · 2023 · Quantitative Imaging in Medicine and Surgery
87. Immune-Related Diarrhea and Colitis in Non-small Cell Lung Cancers: Impact of Multidisciplinary Management in a Real-World Setting
    Laura Bonanno, Martina Lorenzi, Davide Massa, Mattia De Nuzzo, Valentina Angerilli, Fabiana Zingone, Brigida Barberio, Alberto Russi, Fabio Girardi, Alessandra Ferro et al. · 2023 · The Oncologist
88. Dysfunctional intestinal microvascular endothelial cells: Insights and therapeutic implications in gastrointestinal inflammation
    Ji Seok Park, Gail Cresci · 2024 · Immunometabolism
89. Ipilimumab in prostate cancer
    Nishith K. Singh, Ravi Amrit Madan, James L. Gulley · 2012 · Expert Opinion on Biological Therapy
90. Immune Checkpoint Therapies for Melanoma
    Elizabeth Iannotti Buchbinder · 2020 · Hematology/Oncology Clinics of North America
91. Gastrointestinal and liver immune-related adverse effects induced by immune checkpoint inhibitors: A descriptive observational study
    Patricia Sanz-Segura, Paula García Cámara, Eva María Fernández Bonilla, José Miguel Arbonés-Mainar, Vanesa Bernal Monterde · 2021 · Gastroenterología y Hepatología (English Edition)
92. Current status and future perspectives of immunotherapy against urothelial and kidney cancer
    Takashi Kobayashi, Ario Takeuchi, Hiroyuki Nishiyama, Masatoshi Eto · 2021 · Japanese Journal of Clinical Oncology
93. Immune Checkpoint Inhibitors Induced Hepatotoxicity; Gastroenterologists’ Perspectives
    Maham Farshidpour, William R. Hutson · 2022 · Middle East Journal of Digestive Diseases
94. Steroid-Refractory Autoimmune Myocarditis after Pembrolizumab Therapy: Failure of Equine Anti-Thymocyte Globulin to Prevent Heart Failure.
    Nikita Vashi Baclig, Calvin P. Ngo, Albert C. Yeh, Sarah H. Chung, A Cheng, J Grim, Solomon A. Graf, Kai‐Chun Yang · 2019 · PubMed
95. A Brain, A Heart, and the Courage: Balancing Benefit and Toxicity of Immunotherapy in Melanoma
    Yen‐Chou Chen, Muhammad Jaffer, Lylybell Zhou, Javid J. Moslehi, Peter A. Forsyth, Leslie Anne Fecher · 2023 · American Society of Clinical Oncology Educational Book
96. Targeted Combination of Poly(ADP-ribose) Polymerase Inhibitors and Immune Checkpoint Inhibitors Lacking Evidence of Benefit: Focus in Ovarian Cancer
    Morgan Marie Bailey, Susan M. Morand, Rachel Royfman, Leslie Lin, Aditi Puri Singh, Laura Stanbery, Adam Walter, Danae Hamouda, John J. Nemunaitis · 2024 · International Journal of Molecular Sciences
97. Interprofessional Collaboration with Immune Checkpoint Inhibitor Therapy: the Roles of Gastroenterology, Endocrinology and Neurology
    Virginia Jean Seery · 2017 · Seminars in Oncology Nursing
98. Imaging manifestations of immune-related adverse effects in checkpoint inhibitor therapies: A primer for the radiologist
    Vanessa Fiorini Furtado, Kira Melamud, Khalid Hassan, Saurabh Rohatgi, Karen A Buch · 2020 · Clinical Imaging
99. Gastrointestinal Tract Adverse Events
    Hamzah Abu‐Sbeih, Yinghong Wang · 2020 · Advances in experimental medicine and biology